Biogen's (BIIB) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note released on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $311.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on BIIB. Wells Fargo & Company cut Biogen from […]

Related Keywords

Coldstream ,New York ,United States ,Manhattan ,Germany ,Erick Rowinsky ,Piper Sandler ,Stifel Nicolaus ,Priya Singhal ,Biogen Inc ,First Manhattan Co ,Morgan Stanley ,Wells Fargo Company ,Cantor Fitzgerald ,Sohn Co ,Snowden Capital Advisors ,Coldstream Capital Management Inc ,Free Report ,Moderate Buy ,Get Free Report ,Director Eric ,Capital Advisors ,Capital Management ,Systematic Financial Management ,Financial Management ,Biogen Daily ,Biogen ,Nasdaq Biib ,Biib ,Medical ,09062x10 ,Reiterated Rating ,